Aladorian

Drug Profile

Aladorian

Alternative Names: ARM036; ARM036Na; S36; S36Na; S44121; S44121-1; S44121-2

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ARMGO Pharma
  • Developer ARMGO Pharma; Servier
  • Class 2 ring heterocyclic compounds; Acids; Antiarrhythmics; Heart failure therapies; Small molecules; Thiazepines
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Ventricular tachycardia

Most Recent Events

  • 17 Aug 2017 Clinical development is ongoing in Heart failure, arrhythmia and ventricular tachycardia in Europe (ARMGO Pharma pipeline, August 2017)
  • 10 Dec 2014 Clinical development is ongoing in Heart failure, arrhythmia and ventricular tachycardia in Europe
  • 02 Feb 2012 Phase-II clinical trials in Ventricular tachycardia in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top